VEGF-dependent Tumor Angiogenesis Requires Inverse and Reciprocal Regulation of VEGFR1 and VEGFR2

Overview

Journal Cell Death Differ

Specialty Cell Biology

Date 2009 Oct 17

PMID 19834490

Citations 98

Authors

Z Zhang

K G Neiva

M W Lingen

L M Ellis

J E Nor

Affiliations

Soon will be listed here.

Abstract

Vascular endothelial growth factor (VEGF) signaling is critical for tumor angiogenesis. However, therapies based on inhibition of VEGF receptors (VEGFRs) have shown modest results for patients with cancer. Surprisingly little is known about mechanisms underlying the regulation of VEGFR1 and VEGFR2 expression, the main targets of these drugs. Here, analysis of tissue microarrays revealed an inversely reciprocal pattern of VEGFR regulation in the endothelium of human squamous-cell carcinomas (high VEGFR1, low VEGFR2), as compared with the endothelium of control tissues (low VEGFR1, high VEGFR2). Mechanistic studies demonstrated that VEGF signals through the Akt/ERK pathway to inhibit constitutive ubiquitination and induce rapid VEGFR1 accumulation in endothelial cells. Surprisingly, VEGFR1 is primarily localized in the nucleus of endothelial cells. In contrast, VEGF signals through the JNK/c-Jun pathway to induce endocytosis, nuclear translocation, and downregulation of VEGFR2 via ubiquitination. VEGFR1 signaling is required for endothelial-cell survival, while VEGFR2 regulates capillary tube formation. Notably, the antiangiogenic effect of bevacizumab (anti-VEGF antibody) requires normalization of VEGFR1 and VEGFR2 levels in human squamous-cell carcinomas vascularized with human blood vessels in immunodeficient mice. Collectively, this work demonstrates that VEGF-induced angiogenesis requires inverse regulation of VEGFR1 and VEGFR2 in tumor-associated endothelial cells.

Citing Articles

Translationally Controlled Tumor Protein Enhances Angiogenesis in Ovarian Tumors by Activating Vascular Endothelial Growth Factor Receptor 2 Signaling.

Rho S, Kim B, Lee S, Lee C Biomol Ther (Seoul). 2024; 33(1):193-202.

PMID: 39664017 PMC: 11704413. DOI: 10.4062/biomolther.2024.206.

Co-inhibition of PGF and VEGFA enhances the effectiveness of immunotherapy in bladder cancer.

Yang X, Zheng H, Huang J, Liu Y, Li Y, Zhang B Int J Med Sci. 2024; 21(15):2870-2882.

PMID: 39628692 PMC: 11610333. DOI: 10.7150/ijms.100957.

VEGF-B prevents excessive angiogenesis by inhibiting FGF2/FGFR1 pathway.

Lee C, Chen R, Sun G, Liu X, Lin X, He C Signal Transduct Target Ther. 2023; 8(1):305.

PMID: 37591843 PMC: 10435562. DOI: 10.1038/s41392-023-01539-9.

Isolation and anticancer activity of quercetin from L. against breast cancer cell lines MCF-7 and MDA-MB-231.

Chekuri S, Vyshnava S, Somisetti S, Cheniya S, Gandu C, Anupalli R 3 Biotech. 2023; 13(8):289.

PMID: 37547624 PMC: 10397153. DOI: 10.1007/s13205-023-03705-w.

The pathophysiological role of estrogens in the initial stages of pregnancy: molecular mechanisms and clinical implications for pregnancy outcome from the periconceptional period to end of the first trimester.

Parisi F, Fenizia C, Introini A, Zavatta A, Scaccabarozzi C, Biasin M Hum Reprod Update. 2023; 29(6):699-720.

PMID: 37353909 PMC: 10628507. DOI: 10.1093/humupd/dmad016.

References

Mavria G, Vercoulen Y, Yeo M, Paterson H, Karasarides M, Marais R . ERK-MAPK signaling opposes Rho-kinase to promote endothelial cell survival and sprouting during angiogenesis. Cancer Cell. 2006; 9(1):33-44. DOI: 10.1016/j.ccr.2005.12.021. View

Hurwitz H, Fehrenbacher L, Hainsworth J, Heim W, Berlin J, Holmgren E . Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol. 2005; 23(15):3502-8. DOI: 10.1200/JCO.2005.10.017. View

Hibi M, Lin A, Smeal T, Minden A, Karin M . Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev. 1993; 7(11):2135-48. DOI: 10.1101/gad.7.11.2135. View

Karl E, Zhang Z, Dong Z, Neiva K, Soengas M, Koch A . Unidirectional crosstalk between Bcl-xL and Bcl-2 enhances the angiogenic phenotype of endothelial cells. Cell Death Differ. 2007; 14(9):1657-66. DOI: 10.1038/sj.cdd.4402174. View

Yu C, Minemoto Y, Zhang J, Liu J, Tang F, Bui T . JNK suppresses apoptosis via phosphorylation of the proapoptotic Bcl-2 family protein BAD. Mol Cell. 2004; 13(3):329-40. DOI: 10.1016/s1097-2765(04)00028-0. View

Leung D, Cachianes G, Kuang W, Goeddel D, Ferrara N . Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989; 246(4935):1306-9. DOI: 10.1126/science.2479986. View

Casanovas O, Hicklin D, Bergers G, Hanahan D . Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 2005; 8(4):299-309. DOI: 10.1016/j.ccr.2005.09.005. View

Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M . Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 1996; 380(6573):435-9. DOI: 10.1038/380435a0. View

Ferrara N, Gerber H, LeCouter J . The biology of VEGF and its receptors. Nat Med. 2003; 9(6):669-76. DOI: 10.1038/nm0603-669. View

10.

Kerbel R . Tumor angiogenesis. N Engl J Med. 2008; 358(19):2039-49. PMC: 4542009. DOI: 10.1056/NEJMra0706596. View

11.

Fuchs S, Xie B, Adler V, Fried V, Davis R, Ronai Z . c-Jun NH2-terminal kinases target the ubiquitination of their associated transcription factors. J Biol Chem. 1998; 272(51):32163-8. DOI: 10.1074/jbc.272.51.32163. View

12.

Kerbel R, Yu J, Tran J, Man S, Viloria-Petit A, Klement G . Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev. 2002; 20(1-2):79-86. DOI: 10.1023/a:1013172910858. View

13.

Ellis L, Hicklin D . VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008; 8(8):579-91. DOI: 10.1038/nrc2403. View

14.

Takahashi H, Shibuya M . The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond). 2005; 109(3):227-41. DOI: 10.1042/CS20040370. View

15.

Gerber H, Dixit V, Ferrara N . Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem. 1998; 273(21):13313-6. DOI: 10.1074/jbc.273.21.13313. View

16.

Nishimura K, Li W, Hoshino Y, Kadohama T, Asada H, Ohgi S . Role of AKT in cyclic strain-induced endothelial cell proliferation and survival. Am J Physiol Cell Physiol. 2006; 290(3):C812-21. DOI: 10.1152/ajpcell.00347.2005. View

17.

Kim K, Mutter R, Cao C, Albert J, Shinohara E, Sekhar K . Inhibition of signal transducer and activator of transcription 3 activity results in down-regulation of Survivin following irradiation. Mol Cancer Ther. 2006; 5(11):2659-65. DOI: 10.1158/1535-7163.MCT-06-0261. View

18.

Ewan L, Jopling H, Jia H, Mittar S, Bagherzadeh A, Howell G . Intrinsic tyrosine kinase activity is required for vascular endothelial growth factor receptor 2 ubiquitination, sorting and degradation in endothelial cells. Traffic. 2006; 7(9):1270-82. DOI: 10.1111/j.1600-0854.2006.00462.x. View

19.

Miller K, Sweeney C, Sledge Jr G . Can tumor angiogenesis be inhibited without resistance?. EXS. 2004; (94):95-112. DOI: 10.1007/3-7643-7311-3_7. View

20.

Kaneko T, Zhang Z, Mantellini M, Karl E, Zeitlin B, Verhaegen M . Bcl-2 orchestrates a cross-talk between endothelial and tumor cells that promotes tumor growth. Cancer Res. 2007; 67(20):9685-93. DOI: 10.1158/0008-5472.CAN-07-1497. View